Xiong Ying, Shi Liangliang, Zhu Lisheng, Peng Gang
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Oncol. 2021 Sep 20;11:731543. doi: 10.3389/fonc.2021.731543. eCollection 2021.
To evaluate the efficacy and toxicity of the two IC (induction chemotherapy) regimens, TPF (taxanes, cisplatin, and 5-fluorouracil) and TP (taxanes and cisplatin) combined with concurrent chemoradiotherapy (CCRT) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients.
Ultimately, we enrolled 213 patients at stage III-IVA in this retrospective study. The prognosis of TPF and TP was compared by Kaplan-Meier and Cox proportional hazard regression. The toxicities were evaluated according to CTCAE v4.0 and RTOG criteria.
TPF was found to have a higher 5-year DMFS in stage IVA and N2-3 patients. The optimal value of pretreatment SII was 432.48. A further subgroup analysis revealed that patients in stage IVA combined with SII ≥432.48 showed superior OS (=0.038) and DMFS (=0.028) from TPF. Also, SII was proved to be a prognostic element for PFS (HR 2.801, P=0.018) and DMFS (HR 3.735, P=0.032) in multivariate analysis, and IC regimen (HR 2.182, P=0.049) for predicting DMFS. The rate of grade 3-4 leukopenia (=0.038), neutropenia (=0.021), radiation oral mucositis (=0.048), diarrhea (=0.036), and ear damage (=0.046) were more common in TPF group.
Our study revealed that TPF regimen showed a higher 5-year DMFS for stage IVA and N2-3 patients, while for stage III and N0-1, TP might be ample. In high-risk LA-NPC patients (stage IVA combined with pretreatment SII ≥432.48), TPF had a higher 5-year OS and DMFS, with more grade 3-4 toxicities, but most of them were endurable.
评估两种诱导化疗(IC)方案,即TPF(紫杉烷、顺铂和5-氟尿嘧啶)和TP(紫杉烷和顺铂)联合同步放化疗(CCRT)在局部晚期鼻咽癌(LA-NPC)患者中的疗效和毒性。
在这项回顾性研究中,我们最终纳入了213例III-IVA期患者。通过Kaplan-Meier法和Cox比例风险回归比较TPF和TP的预后。根据CTCAE v4.0和RTOG标准评估毒性。
发现TPF方案在IVA期和N2-3期患者中具有更高的5年无远处转移生存率(DMFS)。治疗前系统性免疫炎症指数(SII)的最佳值为432.48。进一步的亚组分析显示,IVA期合并SII≥432.48的患者接受TPF方案时总生存期(OS)(=0.038)和无远处转移生存率(DMFS)(=0.028)更佳。此外,在多变量分析中,SII被证明是无进展生存期(PFS)(风险比[HR] 2.801,P = 0.018)和无远处转移生存率(DMFS)(HR 3.735,P = 0.032)的预后因素,而IC方案(HR 2.182,P = 0.049)可用于预测DMFS。3-4级白细胞减少(=0.038)、中性粒细胞减少(=0.021)、放射性口腔黏膜炎(=0.048)、腹泻(=0.036)和耳部损伤(=0.046)的发生率在TPF组中更为常见。
我们的研究表明,TPF方案在IVA期和N2-3期患者中显示出更高的5年无远处转移生存率,而对于III期和N0-1期患者,TP可能就足够了。在高危LA-NPC患者(IVA期合并治疗前SII≥432.48)中,TPF方案具有更高的5年总生存期和无远处转移生存率,且3-4级毒性更多,但大多数是可耐受的。